We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
RNS just out.
Lombard adding again. Now up to 11.56%.
https://investegate.co.uk/circassia-pharma-plc--cir-/rns/holding-s--in-company/202001271147290242B/
Re. Free float, it’s around 12%. They had to move to AIM from the main market last year as it fell below 25% and its decreased further in recent months. The current significant shareholders are as follows;
Circassia Significant Holdings;
Richard Griffiths - 28.61%
AstraZeneca- 18.9%
Lombard - 10.29%
Oryx - 9.33%
Neptune - 4.77%
Invesco - 4.17%
CIP Merchant Capital - 3.4%
Touchstone Innovations (IP Group) -2.99%
Aviva - 2.6%
Adams - 0.82%
Directors - 2%
Total 87.88%
Invesco almost certainly out, but no TR1 yet, not sure if we’ll get one as they were below 5% and based internationally?
No I am a johnny come lately to both shares. Only discovered them 3 weeks ago and invested with proceeds from just eat and Put ex their split. I am now an enthusiast but less knowledgeable than you I think. What a nice cheerful board.
I also noted Bioventix
missed the original surge and will join if there is a return to 3700
huge institution buying in CCR also been on an amazing rise with KLR
Needed these good runs absolutely stuffed by CARD
Will sell fifty percent of these @ 30 Bruce have you noticed any good signs that I have missed ????
Ft web site shows invesco still have 4.17% neither here nor three. Free float appears to be in the region of 50% much greater than biovexin
And the 2.75m, 1.25m etc. If that’s the end of Invesco then with a free float of 12% this is going to quickly re-rate back to a sensible valuation. It was 52p this time last year with a declining cash pile & no FDA approval for Duaklir. Revenues are now 30% higher & almost at EBITDA breakeven, yet the market cap has halved, this anomaly will close in the coming weeks & months IMO.
Notice all of the trades at 13 grands worth they have to be fund buying. If not someone’s got some balls buying that many. Or they know something we don’t.